TearClear initiates phase 3 trial of preservative-free latanoprost
TearClear has initiated a phase 3 trial evaluating TC-002, a preservative-free latanoprost ophthalmic solution, in patients with glaucoma, according to a press release.
The prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month CLEAR study is investigating the ocular hypotensive efficacy and safety of TC-002 (preservative-free latanoprost ophthalmic solution 0.005%) compared with latanoprost ophthalmic solution 0.005%.
“Enrolling the first subjects is an important milestone,” Stuart Raetzman, CEO of TearClear, said in the release. “We are optimistic that this will allow us to bring the only product to market that keeps BAK safely in the bottle while delivering pristine, preservative-free drops to the eye.”
Read more about